Research & Development News

Cylene Pharmaceuticals is handing off its Phase II compound Quarfloxin and associated anticancer quadruplex-targeting technologies to oncology drug discovery and development company TetraGene

Two impending clinical trials will look at plaque psoriasis treatment.

pSivida has announced that Phase III clinical trials for uveitis treatment are now underway.

TransTech Pharma is looking forward to undertaking Phase III clinical trials to examine how effective TTP488 can be in the treatment of Alzheimer's disease.

Bioline Coating with Recombumin Alpha has been approved for use in Japan.

Company is developing pre-optimized HCP assay kits

A new iron supplement for women has been unveiled by US firm Avion Pharmaceuticals.

WCCT has developed a new tool to help recruit patients to clinical trials.

Cytori Therapeutics' new reagent for use when administering intravascular stem cells to patients has received a CE Mark of approval in Europe.

India-based CRO GVK Biosciences will develop small molecules for Endo.

Tracera promises to detect organic and inorganic trace compounds at the sub parts per million level.

Hydrix from Carnegie is now looking at tapping opportunities in technology transfer and joint product development for range of point-of-care (POC) diagnostics with companies in India.The company is a mobile-wireless technology major and an award winner...

Affordable treatment for the common man should be the focus of any drug development and the important aspect to be considered while engaging in the discovery of drugs is the effective cure for diseases.

The FDA has approved Lantheus Medical's use of its JHS site for manufacturing of the ultrasound imaging agent Definitny Vial.

A clinical trial is underway to see if Oxycyte is safer and tolerable in patients with severe non-penetrating traumatic brain injury.

Clinical trials examining the efficacy of a new treatment for sickle cell disease is to begin in 2014.

A new clinical trial will discover whether a vaccine for herpes is capable of eradicating the disease.

Vulnerable people in particular should seek out a flue vaccine this year.

A new injectible treatment for cholesterol has been approved by the FDA.

Montreal, Canada... Lallemand Inc is pleased to announce the birth of its new division ‘’Lallemand Health Solutions’’.

The two companies wish to identify serological markers to be used as a diagnostic test for CFS.

Arthroplasty discussion to benefit arthritis sufferers in the UAE.

Taipei patients to get dialysis treatment from DaVita.

Myeloma study approved for phase II after successful phase I.

New clinical research has highlighted the benefits of treating metastatic colorectal cancer with SIR-SPheres microspheres.

XenoGesis to research inhalation medicine with view to 'once-a-day' use.

Vaccinations to be developed using adjuvants.

Thalassaemia patients to get oral treatment.

New acquisition involves revolutionary vascular technology.

Drug development to be aided by new biosensor

New grant to encourage plasma transfer research

Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim

Ethris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.

Clinigen Group is managing a patient program for a drug used to treat overexposure to chemotherapy.

FDA approval has been granted to new generic ADHD extended-release tablets from Mallinckrodt.

Evotec has acquired CCS and will integrate its capabilities into existing operations at its Hamburg site.

A clinical trial is to establish whether there is a genetic link to severe asthma.

Cellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and tissue cells.

Asklep has joined the Medidata Solutions Partner Programme to increase the quality and efficiency of clinical trials.

A newly found understanding of receptor signaling may have revealed a better way to design drugs.

An international research have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven ...

A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration.

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer.

Phenex will receive an upfront payment and is eligible to receive development-related milestones.

A review has identified industry sponsorship as an important source of bias in clinical trial reports.

PerkinElmer has added a range of new assay kits to its product portfolio.

PDC Biotech GmbH (PDC) today announced that it has successfully completed a phase I clinical trial for its lead compound for the treatment of preterm labour .

AOP Orphan announces results from phase II trial in PV at ASH Annual Meeting in Atlanta, U.S.A. Promising efficacy and safety data support further development of AOP2014/P1101 AOP2014/P1101 received Orphan Drug designation in 2011 AOP Orphan is init...

A study suggests three or fewer trial sites may be best for phase-I clinical trials.

The research collaboration between Protagonist and Ironwood is being expanded after making 'remarkable' progress.

Sol-Gel Technologies Ltd. announced today positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel.

Innovative nanofleece technology provides high flow rates and total throughput performance in combination with excellent clarification capabilities New series concludes the launch of SSB´s Sartoguard range of prefilters

GSK, Johnson & Johnson and Sanofi are doing the most to improve access to medicines in developing countries.

A novel technology could enable scientists to develop thermostable influenza vaccines.

ACM Global Central Laboratory's new facility in York, England, doubles its laboratory and office space.

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults.

Aptiv Solutions has opened a new office in Durham, NC in a business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Capsugel has opened its new quality control lab in Greenwood, SC, doubling its lab capacity and investing more than $3 million.

Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for thermostable vaccine production.

Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial.

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development.

GBI Research is predicting strong growth in the global cell culture market thanks to increasing demand for biologics and stem cell therapies

Industry representatives and policymakers have met to discuss the future of life sciences research and development in the UK.

Sihuan Pharmaceutical and NeuroVive have announced a collaborative agreement that should help to bring two new cardio-cerebral vascular drugs to market.

A new partnership between Affymetrix and the CPGR in South Africa could ultimately lead to new personalised therapies.

TG Therapeutics and Ildong Pharmaceutical Co have inked a licensing agreement for the development and commercialisation of ublituximab

A report has shed light on pharmaceutical companies' increasing use of adaptive trials.

Shire plc (LSE: SHP, NASDAQ: SHPG) and Boston Children's Hospital today announced a three-year, broad research collaboration in rare diseases.

The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be exploited to combat the disease.

A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell.

Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC).

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment.

Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible...

An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimer’s disease.

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products.

Colby and MannKind have revealed details of a new licensing agreement between the two companies.

Quintiles' latest study could pave the way for more direct-to-patient studies using patient-reported outcomes combined with medical record data.

For many people with high cholesterol, statins serve as the first line of treatment.

Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers.

Resveratrol, a compound found commonly in grape skins and red wine, has been shown to have several beneficial effects on human health, including cardiovascular health and stroke prevention.

Ensemble will use its innovative drug discovery platforms to discover and advance drug candidates against Boehringer Ingelheim's drug targets

Portola, BMS and Pfizer aim to find out whether PRT4445 is a safe and effective antidote to Eliquis and other Factor Xa inhibitors.

Airgas and Biologics Modular are partnering up to provide a flexible, cost-effective solution to companies and manufacturers that need to expand their life science assets.

The potential to replenish populations of cells destroyed by disease was seen by many as the next medical revolution.

Scientists have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis.

A study shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

Cutting Edge Information's latest report sheds light on pharmaceutical companies' expenditure on MSL teams.

Idera has published encouraging results from pre-clinical studies involving TLR 7, 8 and 9.

Phase 1b trials are to get underway to test the efficacy of TRU-016 in treating CLL along with rituximab.

Inhibitors may have utility in autoimmune disease treatment

Demand is growing for the Xoft intraoperative radiation therapy system from iCAD.

ImmunoGen believes its new TAP cancer drug has large potential in the treatment of early stage breast and gastric cancers.

US oncologists are taking a cautious approach to prescribing biosimilar versions of monoclonal antibodies.

Bone marrow cancer drug posts promising results in clinical trials.

The world's first fully integrated, commercially available DNA sequencer will be debuted at the Association of Molecular Pathology conference.

A report has explored the growing trend for medical science liaison teams to support investigator-initiated trials.

Pharmaron will provide drug discovery services to pharmaceutical giant AstraZeneca.

GlaxoSmithKline will allow researchers to access detailed clinical trial data upon request.

Ankylosing spondylitis represents a significantly under-served market, a Frost & Sullivan report says.

Highlights Formulation Knowledge Gap for Challenging Compounds and Outsourcing Priorities

A new production facility is being opened by UCB in Belgium to speed up the process of manufacturing cell cultures for clinical trials.

Growing contract research and development services helped Corgenix post record revenues for the year ended June 30th.

ARIAD Pharmaceuticals has published 'compelling' proof-of-concept data for its new tyrosine-kinase inhibitor AP26113.

Cabozantinib is as effective across four key metrics at doses of 40mg a day as it is at doses of 100mg, according to a new study.

A new assay developed by Promega Corporation is capable of improving cytotoxicity reports from cell cultures gathered within 72 hours.

Doctors tend to be biased against industry-funded clinical trials, a study has found.

Critical Outcome Technologies Inc.announced today new data that broadens the mechanism of action (MOA) of the Company's lead oncology asset, COTI-2, beyond AKT inhibition.

Critical Outcome Technologies Inc. announced today that it has initiated the final series of toxicity experiments in two animal species for its lead oncology asset, COTI-2.

The National Institutes of Health’s National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.